Sibelium: A New Hope for Migraine Relief via Gut-Brain Axis

Research Summary

A recent study published in the journal International Immunopharmacology highlights promising findings on how sibelium (flunarizine) may prevent migraines by targeting the gut-brain axis. Using a mouse model, researchers found that sibelium significantly delayed migraine onset by 32%, reduced head-scratching frequency by 59%, and shortened ear redness duration by 53%. The study showed that sibelium modulates gut microbiota, increasing beneficial bacteria like Lactobacillus and Bifidobacterium and reducing Helicobacter by 85%. It also balanced neurotransmitters and reduced neuroinflammation, offering a potential new approach for migraine intervention by impacting the microbiota-immune-neural network.

Study Details

📄 Title: Sibelium exerts anti-migraine effects by remodeling the gut microbiota and regulating metabolic and immune pathways of the brain-gut axis.

👥 Research Team: Ren Z et al.

📚 Published In: Int Immunopharmacol

📅 Publication Date: 2026 Mar 16

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.